May. 11 at 8:15 PM
$LENZ Q1 '26 Earnings Results & Recap
• Reported GAAP EPS of -
$1.32 down -149.06% YoY
• Reported revenue of
$1.9M
• LENZ Therapeutics believes its existing cash, cash equivalents, and marketable securities of
$258.4M as of March 31, 2026, are sufficient to fund operations for at least the next 12 months and reach positive operating cash flow.
